The recurrent deep intronic pseudoexon-inducing variant COL6A1 c.930+189C>T results in a consistently severe phenotype of COL6-related dystrophy: Towards clinical trial readiness for splice-modulating therapy

Collagen VI-related dystrophies (COL6-RDs) manifest with a spectrum of clinical phenotypes, ranging from Ullrich congenital muscular dystrophy (UCMD), presenting with prominent congenital symptoms and characterised by progressive muscle weakness, joint contractures and respiratory insufficiency, to Bethlem muscular dystrophy, with milder symptoms typically recognised later and at times resembling a limb girdle muscular dystrophy, and intermediate phenotypes falling between UCMD and Bethlem muscular dystrophy. Despite clinical and immunohistochemical features highly suggestive of COL6-RD, some patients had remained without an identified causative variant in COL6A1, COL6A2 or COL6A3. With combined muscle RNA-sequencing and whole-genome sequencing we uncovered a recurrent, de novo deep intronic variant in intron 11 of COL6A1 (c.930+189C>T) that leads to a dominantly acting in-frame pseudoexon insertion. We subsequently identified and have characterised an international cohort of forty-four patients with this COL6A1 intron 11 causative variant, one of the most common recurrent causative variants in the collagen VI genes. Patients manifest a consistently severe phenotype characterised by a paucity of early symptoms followed by an accelerated progression to a severe form of UCMD, except for one patient with somatic mosaicism for this COL6A1 intron 11 variant who manifests a milder phenotype consistent with Bethlem muscular dystrophy. Characterisation of this individual provides a robust validation for the development of our pseudoexon skipping therapy. We have previously shown that splice-modulating antisense oligomers applied in vitro effectively decreased the abundance of the mutant pseudoexon-containing COL6A1 transcripts to levels comparable to the in vivo scenario of the somatic mosaicism shown here, indicating that this therapeutic approach carries significant translational promise for ameliorating the severe form of UCMD caused by this common recurrent COL6A1 causative variant to a Bethlem muscular dystrophy phenotype.

Otto Ullrich, who termed the condition 'Skleratonische Muskeldystrophie' (scleratonic muscular dystrophy), noting evidence of congenital weakness associated with proximal joint contractures and distal joint laxity. 6,77][8][9] At birth, UCMD patients classically demonstrate hypotonia, proximal joint contractures, hip dislocation(s), prominent calcanei and distal joint hyperlaxity, typically resulting in abnormal positioning of the hands and feet (with hands in a position of wrist flexion, resting against the ventral surface of the forearms and feet in a position of dorsiflexion, resting against the anterior surface of the lower leg).Torticollis and kyphoscoliosis can often be seen at birth, as well.While children with UCMD may achieve independent ambulation, this ability is lost in early childhood 1,[9][10][11] typically by 10 years of age. 3,12After becoming wheelchair-dependent, most UCMD patients demonstrate muscle weakness which appears to be relatively stable (as far as can be assessed within restricted range of movement) while joint contractures continue to progress, compounding the motor limitations resulting from the muscle weakness and thus significantly contributing to the overall level of disability. 13While some UCMD patients demonstrate spinal stiffness for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint without an evident spinal curvature, the vast majority develop progressive scoliosis which can appear as early as the preschool years or even congenitally. 3,12An early onset of an invariable decline in respiratory function with early hypoventilation is a salient clinical feature of UCMD, necessitating the initiation of nocturnal non-invasive ventilation by an average age of 11 years. 2,14thlem myopathy (BM) was first described in 1976 by Drs.Jaap Bethlem and George K. van Wijngaarden and is characterised by slowly progressive muscle weakness and distally pronounced joint contractures. 15While often described as a slowly progressive 'myopathy' of adulthood, muscle histology progresses over time to include dystrophic findings, and thus the term 'Bethlem muscular dystrophy' more accurately describes this condition. 16The categorisation of Bethlem muscular dystrophy (MD) within the congenital muscular dystrophies likely relates, in part, to the fact that symptoms of Bethlem muscular dystrophy can present as early as birth.In particular, hypotonia, neck flexion weakness, torticollis and joint contractures are among the early symptoms reported.Progressive contractures of the Achilles tendons and elbows usually manifest by the end of the first decade.Patients with Bethlem MD develop proximal muscle weakness but typically maintain the ability to ambulate into adulthood.By 50 years of age, however, more than 2/3 of patients rely on the use of a wheelchair to aide ambulation, classically for outdoor use while independent ambulation indoors is usually maintained. 17While some adults with Bethlem muscular dystrophy develop nocturnal hypoventilation, this does not occur uniformly, as seen in a large natural history study of pulmonary function in the COL6-RDs which did not demonstrate a statistically significant for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Ullrich congenital muscular dystrophy and Bethlem muscular dystrophy were initially viewed as two separate phenotypic entities; however, subsequently it became apparent that there is a continuous spectrum of phenotypes, with UCMD at the severe end of the spectrum, Bethlem MD along the mild end, and so-called 'intermediate' phenotypes in between the classical UCMD and Bethlem MD phenotypes. 2,3,13,18A large-scale international natural history study of COL6-RD patients helped in elucidating the leads to a dominantly acting in-frame pseudoexon insertion. 19,20Targeted Sanger sequencing for this variant in intron 11 of COL6A1 to complement panel and whole exome testing has revealed that this deep intronic de-novo causative variant is a surprisingly common cause of UCMD.Here we describe the consistent phenotype associated with this COL6A1 intron 11 causative variant, which manifests with a paucity of symptoms congenitally and an accelerated progression to a phenotype of UCMD, except in one patient with somatic mosaicism for this COL6A1 variant who manifests a significantly milder phenotype which is consistent with Bethlem muscular dystrophy.

Study subjects
Patients were identified through their local neurology clinics.Written informed consent and age-appropriate assent for research studies, procedures, and clinical photographs was obtained by a qualified investigator.Ethical approval was obtained via the Institutional Review Board of the National Institutes of Health (protocol 12-N-0095), the University College London Research Ethics Committee (13/LO/1894) and the MRC Centre for Neuromuscular Disease Biobank London Research Ethics Committee (06/Q0406/33).Medical history was obtained, and clinical evaluation, muscle imaging and biopsies, were performed as part of the standard neurologic evaluation.Muscle MRI was performed using conventional T1-weighted spin echo of the lower extremities.
Muscle ultrasound images were obtained using a Siemens/Acuson S2000 with an 18 MHz linear probe.Blood, skin biopsies, muscle biopsies and urine samples were for use under a CC0 license.obtained according to standard procedures.Saliva samples were collected using the oragene-discover kit (DNA Genotek, Ottawa, Canada).

Biospecimen processing
Fibroblasts were cultured from fresh skin biopsies using a standard enzymatic digestion methodology.DNA was extracted from blood, skin fibroblasts, saliva and the pelleted fraction of the urine specimen using the Gentra Puregene Blood kit (Qiagen, Germantown, MD).RNA was obtained from blood following the manual purification of total RNA for human whole blood collected in PAXgene blood RNA tubes protocol (PreAnalytiX/Qiagen, Germantown, MD).RNA was obtained from skin fibroblasts using Trizol (ThermoFisher Scientific, Waltham, MA).For fresh skin biopsy samples, specimens were frozen in liquid nitrogen, pulverized using a mortar and pillar and homogenized in Trizol.DNA and RNA were both obtained using the interphase/organic and the aqueous phase of Trizol, respectively, following manufacturer's instructions.

Pseudoexon amplification and quantification
for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.To quantify the degree of mosaicism, a Taqman assay was designed and synthesized by ThermoFisher Scientific as a Custom Taqman SNP Genotyping Assay, in which the probe hybridizing to the reference (C) allele was labeled with VIC, and the probe hybridizing to the variant (T) allele was labeled with FAM.gDNA samples (between 50 and 600 ng of DNA, depending on the tissue source) were amplified on the Bio-Rad QX200 ddPCR system (Bio-Rad, Hercules, CA) at the NCI CCR Genomics Core, using the standard protocol provided by the manufacturer and the assay described above.
The fractional abundance of the variant (T) allele over the reference (C) allele was calculated from the determined concentrations (copies/µL).
expression.The patient's samples were calibrated with the control (or average of control) samples, following the 2 -ΔΔCt method.

Statistical Analysis
Summary statistics for onset of ambulation, loss of ambulation and onset of noninvasive ventilation were described using mean ± standard deviation.All statistical tests were conducted with a significance level of 0.05.A Mann-Whitney U test was performed to compare the onset of ambulation, loss of ambulation and onset of non-invasive ventilation for UCMD patients heterozygous for the COL6A1 c.930+189C>T variant to UCMD patients with causative variants in the COL6 genes (other than the COL6A1 c.930+189C>T variant).Log-rank tests were performed for the Kaplan-Meier curves.

Results
for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

COL6A1 variant
The COL6A1 c.930+189C>T variant was identified via targeted Sanger sequencing (N=27), 20 performed in our laboratory on DNA samples for patients with a clinical phenotype of COL6-RD who remained without an identified causative variant in the COL6 genes (COL6A1, COL6A2 and COL6A3) on panel or whole exome sequencing, or so-called 'causative variant negative' COL6-RD, and following the initial identification of this variant via RNA sequencing performed in muscle biopsy samples from patients with COL6-RD who were 'causative variant negative' (N=4). 19Following the inclusion of this variant on diagnostic next generation sequencing panels, it was identified in further patients (N=13), with one of these patients with evidence of somatic mosaicism for the COL6A1 c.930+189C>T variant.

Demographic and clinical features are listed in Table
Three patients were included in a report of a cohort of patients with COL6-RD in Italy. 21r use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint Phenotypic data on the clinical presentation of patients with a phenotype of UCMD due to causative variants in the COL6 genes other than the COL6A1 c.930+189C>T variant were evaluated to serve as a comparison cohort to the COL6A1 c.930+189C>T specific cohort.Seventeen patients with UCMD, 12 females and 5 males evaluated at the National Institutes of Health (NIH) were included in this comparison cohort (Supplementary Table 1).
The age at the time of the clinical evaluation ranges 3-38 years.Twenty-nine patients had lost independent ambulation (as defined by full-time wheelchair dependence) at the time of the clinical evaluation, with a mean age at loss of ambulation of 8.0 ± 3.0 years (Fig. 1B and C).Twenty-four patients had started non-invasive ventilation (NIV) in the form of bilevel positive airway pressure at the time of the clinical evaluation, at a mean age of 11.9 ± 4.4 years (Fig. 1B and D).Two patients in this cohort died: patient US9 during his 20s from probable cor pulmonale, in the setting of refusal to use non-invasive for use under a CC0 license.holding onto the railing.She demonstrated the ability to ambulate independently with a Trendelenburg gait and was able to run with an exaggerated arm swing.Pulmonary function testing demonstrated a forced vital capacity (FVC) of 91% predicted upright and 79% predicted supine.There was evidence of only mild contractures of the long finger flexors and Achilles tendons and hyperlaxity of the elbow joints (Fig. 2F).There was no evidence of scoliosis.

COL6 genes (other than the COL6A1 c.930+189C>T variant)
Of those patients with findings documented at birth, 88% (15/17) had hip dislocation and/or hip dysplasia, 63% (10/16) had evidence of hypotonia, 38% (6/16) had abnormal positioning of hands and feet, and 25% (4/16) had torticollis (Fig. 1A).All patients had attained independent ambulation at a mean age of 1.6 ± 0.5 years (Fig. 1B).The age at the time of clinical evaluation ranges 5 to 29 years.Fifteen patients had lost independent ambulation (as defined by full-time wheelchair dependence) at the time of the clinical evaluation, with a mean age at loss of ambulation of 7.1 ± 2.6 years (Fig. 1B   and C).Twelve patients had started non-invasive ventilation (NIV) in the form of bilevel positive airway pressure at the time of the clinical evaluation, at a mean age of 8.9 ± 2.3 years (Fig. 1B and D).One patient in this cohort died during the teenage years in the setting of respiratory failure and failure to thrive.

Comparison of the phenotype of 'classical UCMD' and the phenotype of 'COL6A1 Intron 11'
for use under a CC0 license.
There was a statistically significant difference between 'classical UCMD' (due to causative variants in the COL6 genes other than the COL6A1 c.930+189C>T variant) and the 'COL6A1 Intron 11' phenotype (due to heterozygosity for the COL6A1 c.930+189C>T variant) for the mean age at onset of independent ambulation (p = 0.04) while there was no statistically significant difference for the mean age at loss of ambulation (p = 0.32) (Fig. 1B).The difference between the mean age at onset of NIV between patients with classical UCMD and patients with the COL6A1 Intron 11 phenotype was statistically significant (p = 0.009) (Fig. 1B).Kaplan-Meier curves depicting the probability of independent ambulation (Fig. 1C) for patients with classical UCMD and COL6A1 Intron 11 did not demonstrate a statistically significant difference (p = 0.07) while Kaplan-Meier curves depicting ventilation-free probability (Fig. 1D) demonstrated a statistically significant difference (p = 0.0009).
for use under a CC0 license.
Muscle ultrasound was performed in eight patients at the National Institutes of Health and demonstrated significantly increased echogenicity in a granular quality and a 'central cloud' pattern of increased echogenicity along the central fascia of the rectus femoris muscle and an 'outside-in' pattern of increased echogenicity along the outer region of the vastus lateralis, a classic muscle ultrasound pattern in patients with COL6-RD 23 with loss of bone echogenicity, as appreciated in muscle ultrasound images (Fig. 3B and C).Muscle ultrasound performed in the mosaic patient US16 demonstrated increased echogenicity in a 'central cloud' pattern in the rectus femoris muscle with generally increased echogenicity in the vastus lateralis and maintenance of bone echogenicity (Fig. 3E and F), in contrast to patients heterozygous for COL6A1 (c.930+189C>T) in whom bone echogenicity was lost due to the degree of increased echogenicity of muscles.

Muscle immunofluorescence
Collagen VI immunofluorescence when performed on available muscle biopsy tissue demonstrated mislocalisation of collagen VI immunoreactivity, which was found to be accumulated in the interstitial space instead of colocalising with laminin at the basement membrane, as demonstrated in confocal microscopy images of the muscle biopsy of patient US1 (Fig. 4).

Somatic mosaicism for COL6A1 c.930+189C>T
for use under a CC0 license.Patient US16 was found to have somatic mosaicism for COL6A1 c.930+189C>T based on Sanger sequencing of genomic DNA performed in various tissues (Fig. 5A).The degree of mosaicism, calculated from the fractional abundance (or percent) of the variant ('T') allele as measured by digital droplet PCR, was determined to be ~20%, meaning that approximately 40% of cells in this individual harbour the c.930+189C>T variant (Fig. 5B).Tissues tested were derived from the endoderm (bladder epithelium in the urine sample), the mesoderm (blood cells, dermis of the skin biopsy sample), or the ectoderm (epidermis of the skin biopsy sample, buccal epithelium in the saliva sample) (Fig. 5B).Consistent with this finding, expression levels of COL6A1 transcripts including the pseudoexon as assessed in a fresh skin biopsy sample, and in cultured dermal fibroblasts, were lower in US16 compared to samples obtained in patients heterozygous for COL6A1 c.930+189C>T (Fig. 5C).By quantitative PCR performed in fresh skin biopsies, we determined that the COL6A1 transcripts with inclusion of the pseudoexon were 7.2-fold lower in the patient with somatic mosaicism for COL6A1 c.930+189C>T (US16) compared to a patient heterozygous for COL6A1 c.930+189C>T (US5) (Fig. 5D), although additional samples would be needed to determine statistical significance.

Discussion
The COL6-related dystrophies typically manifest symptoms at birth and thus are at their core congenital muscular dystrophies.The COL6-RD subtype Ullrich congenital muscular dystrophy (UCMD) is characterised by prominent symptoms at the time of birth including significant hypotonia, proximal joint contractures, distal hyperlaxity, abnormal positioning of the hands and feet, prominent calcanei, hip dislocation(s), for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.7][8][9] Here we report an international cohort of 44 patients all habouring a de novo COL6A1 c.930+189C>T deep intronic pseudoexon-inducing variant, and we delineate their presentation and natural history in comparison to patients with classical UCMD.
A hallmark of this COL6A1 c.930+189C>T-specific cohort is that all patients who are heterozygous for this causative variant (N=43) demonstrate a paucity of congenital symptoms, followed by an apparent accelerated progression of symptoms, ultimately demonstrating a phenotype consistent with the well-defined phenotype of UCMD (as distinguished from other COL6-RD phenotypes), 2,12,14,25 what we will refer to as 'classical UCMD.'In fact, only approximately one third or less of the patients heterozygous for COL6A1 c.930+189C>T had evidence of any symptoms at birth.Furthermore, with a mean age of 1.4 years at the onset of independent ambulation, most patients in this COL6A1 c.930+189C>T-specific cohort did not present to a neurologist until the time of delayed independent ambulation or afterwards, when evidence of difficulty arising from the floor, or frequent falls were noted.In contrast, in a comparison cohort of patients with the UCMD phenotype who do not harbour the COL6A1 c.930+189C>T variant (N=17), symptoms at birth were present in up to 88%, thus typically prompting a neurological evaluation congenitally.
The mean age at loss of independent ambulation in this COL6A1 c.930+189C>Tspecific cohort is 8.0 ± 3.0 years, which is not statistically different from our comparison cohort of patients with classical UCMD (non COL6A1 c.930+189C>T UCMD; N=17) of for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Of note, while this mean age is statistically different from the mean age at the time of NIV initiation of 8.9 ± 2.3 in our comparison cohort of classical UCMD, it is similar to the data in the largest international natural history study of pulmonary function in patients with UCMD (N=75) in which the mean age at the time of NIV initiation was 11.3 ± 4.0 years 2 (Fig. 6).Given differences in practice among centres internationally relating to frequency of pulmonary function testing and polysomnogram assessments as well as thresholds for starting NIV, it likely would be more accurate to compare the international COL6A1 c.930+189C>T-specific cohort (N=43) to the international classical UCMD cohort (N=75) than to the comparison cohort of classical UCMD (N=17) evaluated at one center where the initiation of NIV tends to be more proactive.
Overall, what distinguishes this COL6A1 c.930+189C>T-specific cohort phenotype from the classical UCMD phenotype is a delayed and then accelerated rate of progression of symptoms in comparison to classical UCMD, in which striking symptoms are evident at the time of birth (Fig. 6).All patients who are heterozygous for this causative COL6A1 intron 11 variant (not with somatic mosaicism) ultimately arrive at a highly consistent clinical severity of motor and likely also pulmonary function (depending on the comparator cohort), characterised by loss of ambulation and respiratory insufficiency at approximately the same age as classical UCMD, despite manifesting first symptoms at a mean age of 1.4 ± 0.3 years (Fig. 6).Given this convergence of phenotypic features in patients in this COL6A1 c.930+189C>T-specific cohort and patients with classical for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint UCMD, outcome measures validated in patients with the classical UCMD phenotype could be used for patients with the COL6A1 Intron 11 phenotype. 26,27 COL6-RDs, respiratory insufficiency is largely due to disproportionate weakness of the diaphragm. 2,28In this particular cohort of patients with de novo COL6A1 c.930+189C>T, it is possible that the severity of joint contractures may contribute to further decreasing the compliance of the chest wall, thus likely further exacerbating patients' respiratory insufficiency.It is important to note that the two patients in this cohort who passed away had evidence of severe respiratory insufficiency as well as severe joint contractures (greater than 90 degrees).Patient US9 had been prescribed NIV in the form of bilevel airway pressure during the teenage years but refused to use NIV and passed away in his 20s (with last recorded FVC of 21% three years prior to his death).Patient CA3 had evidence of respiratory failure (with last recorded FVC of 8%) and failure to thrive prior to passing away in his 30s.
3][24] Thus, muscle imaging remains a very helpful tool in supporting efforts to identify a causative variant in the COL6 genes in the setting of a clinical suspicion of COL6-RD.Furthermore, muscle immunohistochemistry studies in patients harbouring COL6A1 c.930+189C>T demonstrate mislocalised collagen VI expression, as classically seen in COL6-RD due to dominant mutational mechanisms. 5Thus, in the setting of clinical examination for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint findings and muscle imaging findings suggestive of COL6-RD as well as in the setting of evidence of mislocalisation of collagen VI on muscle immunohistochemistry, it is essential to consider the diagnostic possibility of COL6-RD due to COL6A1 c.930+189C>T and to ensure that genetic testing laboratories adequately assess for the presence of this deep intronic variant.
The exact pathomechanisms by which the COL6A1 c.930+189C>T causative variant results in a severe phenotype of UCMD with an accelerated progression of symptoms in comparison to classical UCMD were partially elucidated.Strikingly, we found that approximately 25% of total COL6A1 transcripts include the 72-nt pseudoexon in muscle tissues, as opposed to the expected 50%, due to the "leakiness" of the c.930+189C>T variant, 19,20 which could explain the initial delay in the presentation of symptoms.The mutant collagen α1(VI) protein produced includes a stretch of 24-amino acid residues that disrupts the Gly-X-Y repeat in its amino-terminus, 20 prior to the cysteine residue involved in dimerisation, a 'hot-spot' where dominant-negative COL6 variants are known to allow mutant chains' assembly into tetramers.It can thus be assumed that the mutant collagen α1(VI) protein containing the pseudoexon-encoding sequence exerts a dominant-negative effect by assembling into tetramers and consequently disrupting polymerisation of collagen VI tetramers.In fact, costaining with a mutation-specific antibody and a collagen α3(VI)-N-terminus-specific antibody showed a broad overlap in immunofluorescence microscopy in patient muscle. 29However, when patient fibroblast cell culture supernatants were studied by composite agarose/polyacrylamide gel electrophoresis and immunoblotting, it was found that the mutant collagen α1(VI) was for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint secreted as single chains. 29Interestingly, like in the supernatant from healthy control fibroblasts, wild-type collagen VI tetramers were found in the supernatant of patient fibroblast cultures.Indeed, in negative stain electron micrographs of immunogoldlabelled supernatants of patient fibroblasts, collagen VI microfibrils with the typical spacing of the globular beads were detected with a gold-labeled collagen α3(VI)-Nterminus antibody.In contrast, the gold-labelled mutation-specific antibody bound to protein aggregates and sometimes decorated collagen VI microfibrils. 29The two effects of aggregated mutant collagen α1(VI) chains and the decoration of collagen VI microfibrils are not mutually exclusive and could be cumulative, which may explain the acceleration of clinical symptoms once the disease starts.
The strikingly milder clinical phenotype observed in patient (US16) who has somatic mosaicism for the COL6A1 c.930+189C>T variant, for whom expression of pseudoexon transcripts was 7.2-fold lower compared to the heterozygous patient US5 (as assessed in respective skin biopsies), highlights how in principle a reduction in the abundance of the pseudoexon would translate to an amelioration of clinical symptoms.In particular, the observation that patient US16 continues to ascend and descend stairs without use of the railing suggests a phenotype consistent with Bethlem muscular dystrophy. 25In keeping with this patient's milder motor phenotype is her mildly affected pulmonary function, with an FVC of 91% upright and 79% supine.Thus, this patient represents an in vivo scenario of our previously published in vitro rescue of the pseudoexon insertion with splice-modulating antisense oligomers which effectively decreased the levels of for use under a CC0 license.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 29, 2024.; https://doi.org/10.1101/2024.03.29.24304673 doi: medRxiv preprint pseudoexon transcripts by ~7-fold (for PMO-PEX1, at the highest concentration tested, in cultured fibroblasts) and consequently levels of the aberrant protein product. 20ken together, given the clinical severity of UCMD described in this large international cohort of patients harbouring COL6A1 c.930+189C>T, the recognition that this variant is one of the most common recurrent causative variants in COL6-RDs and the promise of therapeutic rescue as demonstrated by our pseudoexon skipping/splice-modulating in vitro work, 20,30,31 it is imperative that patients harbouring this deep intronic variant are clinically recognised and diagnosed.To this end, it is necessary for next generation sequencing panels to include an algorithm to ensure that intron 11 of COL6A1 is captured, including libraries built for high throughput which would capture this variant.c.930+189C>T variant-specific splice-modulating therapeutic approach in development. 20,30,31This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Please contact the corresponding author for access to these clinical images.This article is a US Government work.It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Please contact the corresponding author for access to these clinical images, which were removed due to medRxiv policy.
parameters of intermediate COL6-RD.Patients in this group uniformly achieved ambulation and walked longer than UCMD patients but never achieved the ability to jump or run, in contrast to patients with Bethlem MD.For this intermediate COL6-RD group, loss of ambulation occurred by approximately 19 years of age, and nocturnal non-invasive ventilation (NIV) was needed by approximately 21.5 years of age. 2 Anticipatory care of the uniformly progressive decline in respiratory function which characterises UCMD and intermediate COL6-RD, including the timely initiation of noninvasive ventilation, is essential for decreasing morbidity and mortality, and this care relies on the clinical recognition of COL6-RD.Despite clinical and immunohistochemical features highly suggestive of COL6-RD, some patients have remained without an identified causative variant in the COL6A1-3 genes.By using a combination of muscle RNA-seq and whole-genome sequencing in four such patients, we uncovered a recurrent, de-novo deep-intronic variant in intron 11 of COL6A1 (c.930+189C>T) that for use under a CC0 license.
ventilation and patient CA3 during his 30s in the setting of respiratory failure and failure to thrive.Joint contractures at the elbows, knees and wrists were assessed on clinical examination and categorised as 'mild': <45 degrees, 'moderate': 45 to <90 degrees and 'severe': >90 degrees.At the time of clinical evaluation, 7 (16%) patients had 'mild' joint contractures (ages 4-10 years), 16 (37%) patients had 'moderate' joint contractures (ages 3-16 years), and 20 (47%) patients had 'severe' joint contractures (ages 7-38 years) (Fig.2A-E).Scoliosis requiring surgical repair was reported in 39% (15/38) patients with surgery performed in 10 patients, ranging in age at the time of surgery of 6-15 years.Three families declined scoliosis surgery, and two families opted to continue to observe the scoliosis at the time of the last assessment.Phenotype of patient with somatic mosaicism for the COL6A1 c.930+189C>T variantPatient US16 has a distinctly milder clinical phenotype.Her mother denied noting evidence of decreased fetal movement during the pregnancy.At the time of birth, hypotonia was noted, but there was no evidence of hip dislocation and/or hip dysplasia, abnormal positioning of hands and feet or torticollis.Patient US16 achieved independent ambulation without noted delay.At the time of her last clinical evaluation (first decade of life), she maintained the ability to ascend and descend stairs without for use under a CC0 license.
Moreover, we suggest designating the COL6A1 c.930+189C>T-specific phenotype described here as a 'COL6A1 Intron 11' phenotype, given the need to distinguish this phenotype characterised by a delayed onset of clinical symptoms followed by an accelerated progression of symptoms from other patients with COL6-RD for the purpose of natural history studies in preparation for future clinical trials.Distinguishing this socalled 'COL6A1 Intron 11' phenotype is essential from the perspective of inclusion criteria for clinical trial stratification, including for non-variant-specific therapeutic approaches for COL6-RDs, such as therapeutic approaches targeting TGFβ, fibrosis and apoptosis.Our characterization of this COL6A1 c.930+189C>T-specific cohort including the comparative retrospective natural history of patients with COL6A1 Intron 11 to patients with classical UCMD contributes to the clinical trial readiness of the COL6A1 Intron 11 patient population, who are facing the promise of the COL6A1 for use under a CC0 license.

Table 1 :Figure 1 :
Figure 1: Clinical phenotype of patients heterozygous for the COL6A1 c.930+189C>T variant versus patients with Classical UCMD (UCMD patients who do not have the COL6A1 c.930+189C>T variant)

Figure 2 :
Figure 2: Joint contractures in heterozygous patients versus a patient with somatic mosaicism for COL6A1 (c.930+189C>T) (A) Mild elbow contractures already noticeable in Patient US1; (B) Severe long finger flexor contractures in Patient IR1; (C) Severe wrist flexion and long finger flexor contractures in Patient US9; (D) Severe elbow, wrist flexion and long finger flexor contractures in Patient US5; (E) Severe elbow contracture (greater than 90 degrees in elbow flexion) in Patient US2.(F) Joint hyperlaxity of the elbow in Patient US16, who has somatic mosaicism for COL6A1 (c.930+189C>T).

Figure 3 :
Figure 3: Muscle MRI and ultrasound in a heterozygous patient versus a patient with somatic mosaicism for COL6A1 (c.930+189C>T) (A) Axial TI MRI of the upper leg in patient US10 demonstrating abnormal signaling consistent with a 'central cloud' pattern in the rectus femoris (black arrows) and an 'outside in' pattern in the vastus lateralis (white arrowheads); (B) Ultrasound of the rectus femoris (RF) muscle in patient US10 demonstrating abnormal signaling consistent with a 'central cloud' pattern (white arrow) with a loss of bone echogenicity; (C) Ultrasound of the vastus lateralis (VL) muscle in patient US10 demonstrating increased echogenicity with a loss of bone echogenicity; (D) Axial TI MRI of the upper leg in patient US16 demonstrating mildly abnormal signaling in the vastus lateralis muscle suggestive of a subtle 'outside in' pattern (black arrowheads); (E) Ultrasound of the rectus femoris (RF) muscle in patient US16 demonstrating an increase in echogenicity of the rectus femoris (RF) muscle consistent with a 'central cloud' pattern (white arrow) with bone echogenicity (asterisk) preserved; (F) Ultrasound of the vastus lateralis (VL) muscle in patient US16 demonstrating an increase in echogenicity of the vastus lateralis (VL) with bone echogenicity (asterisk) preserved.

Figure 4 :Figure 5 :
Figure 4: Muscle Immunofluorescence Confocal imaging of muscle co-stained with collagen VI (red) and basement membrane marker laminin (green) along with nuclear stain DAPI (blue).(A) In control muscle, collagen VI is co-localised with laminin at the basement membrane.(B) In the muscle of patient US1 from a biopsy, collagen VI signal is observed in the interstitial space, indicative of collagen VI mislocalisation relative to the basement membrane.(magnification = 63X; scale bar = 75µm)

Figure 6 :
Figure 6: Comparison of the COL6A1 Intron 11 Phenotype and the Classical UCMD Phenotype (A) Schematic of the natural history of the motor and pulmonary function in patients with the classical UCMD phenotype in the comparison cohort (N=17).Natural history of pulmonary function data from the largest published international natural history study of patients included (N=75) 2 (dotted line).(B) Schematic of the natural history of motor and pulmonary function in this cohort of patients who are heterozygous for COL6A1 (c.930+189C>T) (N=43)

Figure 6 International published data 2 :
Figure 6